Trials / NCT04008771
Intravitreal Injection of SeeQ CdSe 655 Alt Nanoparticles for Patients With Degenerative Retinal Diseases
Completed N/A Drug / neuroprotection
- Sponsor
- 2C Tech Corp
- Treatment
- SeeQ CdSe 655 ALT
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 21 Years to no upper limit
- Enrollment
- 20 participants
- Started
- 2014-01-06
- Main results expected
- 2014-12-19
- Results posted
- Not yet
- Record last updated
- 2019-07-05
What the study is testing
This study was a prospective, open label feasibility study conducted at a single clinical site (APEC, Mexico City) to evaluate the safety and preliminary effectiveness of the SeeQ device, with each patient's serving as his/her own contralateral control.
Where it runs
Mexico (1)
- Asociacion Para Evitar La Ceguera En Mexico, I.A.P. (APEC), Mexico City